NUTXNutex Health Inc.
Is the price fair?
Undemanding: modest expectations priced in and cheap vs its sector.
Priced for a decline (~−18% a year). The price demands less than its three-year revenue growth of 62% a year, expectations look modest.
Sector median 22.6× across 130 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.
All from derived, as of Jun 30, 2026.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What NUTX's price assumes
Nutex Health Inc. trades at 8.16× earnings against 20.0× for the median Medical Care Facilities name, cheaper than its own group.
Trailing P/E · Medical Care Facilities median 20.0 · cheaper than the typical name in its group
- Price / sales
- 1.21
Price / sales · today's price, trailing year to Jun 30, 2026
- Free cash flow yield
- 27%
Free cash flow yield · Medical Care Facilities median 7.1%
- Growth the price implies
- −18%
Growth the price implies · The price pays for −18% free cash flow growth a year for a decade; revenue has grown +62% a year over the last three.
Details›
- Price / booktoday's price, trailing year to Jun 30, 2026
- 2.60
- EV / EBITtoday's price, trailing year to Jun 30, 2026
- 2.36
- EV / salestoday's price, trailing year to Jun 30, 2026
- 1.02
- Healthcare median P/E509 names
- 26.2
- Medical Care Facilities median P/E33 names
- 20.0
- Free cash flow, trailing twelve months
- $274M
- Market capitalisation
- $1.03B
- 3-year revenue growth
- +62%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.